Teriparatide

Also known as: PTH(1-34) · rhPTH(1-34) · Forteo · Forsteo

FDA-approved

Last verified: October 30, 2026

At a glance

FDA approval FDA-approved 8 applications

Randomized controlled trials 301 of 4,491 publications on PubMed

Registered clinical trials 199 18 active

Adverse event reports 117,891 47,322 classified as serious

Teriparatide is an FDA-approved drug, marketed as Forteo, Bonsity, Teriparatide (first approval: November 26, 2002).
PubMed lists 4,491 publications mentioning it, including 301 randomized controlled trials and 855 animal-only studies.
ClinicalTrials.gov lists 199 registered studies testing it (18 active).
FDA's adverse event system (FAERS) holds 117,891 reports mentioning it; 47,322 classified as serious. Reports do not prove causation.

Research topics

Bone Density Conservation Agents 65
Bone Density 44
Osteoporosis 43
Parathyroid Hormone 25
Osteoporotic Fractures 19
Denosumab 15
Diphosphonates 14
Antibodies, Monoclonal 12
Bone Remodeling 12
Parathyroid Hormone-Related Protein 11

Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).

Regulatory status

Drugs@FDA applications

Application	Product	Status	First approval	Sponsor
NDA021318	FORTEO	Approved, marketed	November 26, 2002	LILLY
NDA211939	BONSITY	Approved, marketed	October 4, 2019	ALVOGEN
ANDA208569	TERIPARATIDE	Approved, marketed	November 16, 2023	TEVA PHARMS USA
ANDA211097	TERIPARATIDE	Approved, marketed	November 16, 2023	APOTEX
NDA218771	TERIPARATIDE	Approved, marketed	June 4, 2024	ALMAJECT
ANDA213641	TERIPARATIDE	Approved, marketed	December 12, 2025	AMPHASTAR PHARMS INC
ANDA214412	TERIPARATIDE	Approved, marketed	October 23, 2026	DR REDDYS
NDA019498	PARATHAR	Approved, discontinued	—	SANOFI AVENTIS US

Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query

FDA compounding safety list

Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.

Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026

Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.

Scientific publications

All publications 4,491
Human (MeSH) 2,807
Animal only 855
Clinical trials 375
Randomized controlled trials 301
Systematic reviews & meta-analyses 169
Case reports 348
Retracted 2

Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.

Latest publications

Bone response to intermittent parathyroid hormone (PTH) is both genetic and sex specific in mice. Animal study 2027 Bone
Combined Teriparatide and Exercise Effects on Diabetic Skeletal Muscle Ultrastructure. Animal study 2026 In vivo (Athens, Greece)
Regenerative Strategies for Osteoporotic Craniomaxillofacial Bone Defects: Evidence, Translational Gaps, and Future Directions. Review 2026 Biomedicines
Teriparatide Topical Delivery Supports Osseointegration in Ovariectomized Rats Receiving Cafeteria Diet and Bisphosphonate: An In Vivo Experimental Study. Unclassified 2026 Clinical oral implants research
Bone-targeting engineered exosomes delivering teriparatide mRNA for the treatment of osteoporosis. Unclassified 2026 Regenerative therapy
Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults. Review 2026 The Annals of pharmacotherapy
Emerging therapeutic strategies for medication-related osteonecrosis of the jaw: From microenvironmental modulation to precision medicine (Review). Review 2026 Experimental and therapeutic medicine
Near-infrared-activated CuTA@PDA@PTH nanozymes remodel the osteoarthritic microenvironment for coordinated cartilage protection and subchondral bone repair. Human study 2026 Journal of nanobiotechnology
Prevention and treatment of osteoporosis in postmenopausal women. Unclassified 2026 Post reproductive health
Beyond antifracture efficacy: Osteoanabolic versus antiresorptive therapy for chronic pain after osteoporotic vertebral fractures. A systematic review and meta-analysis. Review 2026 Bone

Source: PubMed (NCBI) · verified October 30, 2026

Clinical trials

Registered: 199
Active: 18
With posted results: 70

Conditions studied

Osteoporosis 90
Osteoporosis, Postmenopausal 19
Hypoparathyroidism 15
Postmenopausal Osteoporosis 15
Bone Loss 5
Osteoporosis, Post-Menopausal 5
Endocrine System Diseases 4
Parathyroid Diseases 4
Spinal Cord Injury 4
Osteopenia 4
Postmenopausal Women With Osteoporosis 3
Osteoporotic Fractures 3

Study	Status	Phase	Start
PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot) NCT06303284 University of Calgary	Not yet recruiting	Phase 1, Phase 2	March 15, 2027
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism NCT07081997 Ascendis Pharma Bone Diseases A/S	Recruiting	Phase 3	May 7, 2026
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens NCT07579936 Shenzhen Salubris Pharmaceuticals Co., Ltd.	Recruiting	Phase 2	April 30, 2026
A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants NCT07497503 Syneos Health	Recruiting	Phase 1	April 10, 2026
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture NCT06898060 Qilu Pharmaceutical Co., Ltd.	Not yet recruiting	Phase 3	Jun 2025
Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis NCT06951776 Peking University Third Hospital	Not yet recruiting	N/A	May 1, 2025
Combined Anabolic Therapy NCT06558188 Massachusetts General Hospital	Recruiting	Phase 4	February 3, 2025
Precision Medicine Approach for Osteoporosis - Follow Up Study NCT06264609 Paul F Netzel	Enrolling by invitation	Phase 4	February 1, 2024
Sequential Therapies After Osteoanabolic Treatment NCT06164795 424 General Military Hospital	Recruiting	—	November 25, 2023
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture NCT05866029 Peking Union Medical College Hospital	Recruiting	N/A	May 26, 2023

Show 40 more studies

Study	Status	Phase	Start
Relationship Between Thoracic Hyperkyphosis and Fall Risk in Women with Fragility Vertebral Fractures NCT06842758 University of Palermo	Active, not recruiting	—	May 1, 2023
Fracture Recovery for Returning to Duty (Teriparatide STRONG) NCT04589819 University of South Carolina	Enrolling by invitation	Phase 4	December 8, 2022
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover NCT05151484 Madhumathi Rao	Active, not recruiting	Phase 4	March 21, 2022
Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease NCT04522622 Ditte Hansen	Recruiting	Phase 4	December 15, 2021
Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery NCT03770338 The University of Hong Kong	Active, not recruiting	N/A	March 1, 2019
Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP NCT03692143 Nanfang Hospital, Southern Medical University	Active, not recruiting	—	January 1, 2017
Teriparatide (PTH) and Bone Strength in Postmenopausal Women NCT01155245 University Health Network, Toronto	Active, not recruiting	—	Jun 2008
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis NCT01155232 University Health Network, Toronto	Active, not recruiting	—	Nov 2004
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis NCT07242612 Khyber Medical University Peshawar	Completed	N/A	October 1, 2025
A Study of TeriQ Patch in Healthy Adult Female Participants NCT06644040 QuadMedicine	Completed	Phase 1	October 25, 2024
Teriparatide on Maxillary Sinus Floor Osseointegration NCT06061354 Universidad de Valparaiso	Unknown status	Phase 4	August 23, 2023
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo NCT05965167 Entera Bio Ltd.	Completed	Phase 1	May 11, 2023
Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule NCT05164614 RANI Therapeutics	Completed	Phase 1	February 21, 2022
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk NCT07028320 Shenzhen Salubris Pharmaceuticals Co., Ltd.	Completed	Phase 3	December 3, 2021
PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism NCT05387070 Visen Pharmaceuticals (Shanghai) Co., Ltd.	Completed	Phase 3	July 28, 2021
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women NCT04974723 Radius Health, Inc. Results posted	Completed	—	July 1, 2021
Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile. NCT05369013 STADA, Spain	Unknown status	—	June 15, 2021
Weekly Use of Teriparatide to Accelerate Healing of Distal Radius Fracture NCT04473989 Peking University Third Hospital	Unknown status	Phase 2	June 1, 2021
Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes NCT04921124 Norfolk and Norwich University Hospitals NHS Foundation Trust	Completed	Phase 3	May 24, 2021
Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). NCT04750460 Saint Petersburg State University, Russia	Completed	Phase 3	March 1, 2021
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism NCT04701203 Ascendis Pharma Bone Diseases A/S Results posted	Completed	Phase 3	February 16, 2021
Effect of Vitamin K Supplementation on Circulating Levels of Osteocalcin on the Bone Metabolism and Aging NCT04669782 University of Milano Bicocca	Terminated	N/A	November 24, 2020
Post-fracture Medication and Mortality NCT05366621 National Cheng-Kung University Hospital	Completed	—	November 1, 2020
Replication of the VERO Osteoporosis Trial in Healthcare Claims Data NCT04879420 Brigham and Women's Hospital	Completed	—	October 29, 2020
Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression Fracture NCT05018637 Inbo Han	Unknown status	Phase 2	September 1, 2020
Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults NCT04747392 Shenzhen Salubris Pharmaceuticals Co., Ltd.	Completed	Phase 1	August 19, 2020
Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis NCT03217513 Edward Fox	Withdrawn	—	January 1, 2020
Study of Teriparatide in Stress Fracture Healing NCT04196855 University of East Anglia	Unknown status	Phase 3	December 23, 2019
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration NCT04026256 Massachusetts General Hospital Results posted	Completed	Phase 4	September 2, 2019
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism NCT04009291 Ascendis Pharma A/S Results posted	Completed	Phase 2	August 27, 2019
Novel Combination Therapy for Osteoporosis in Men NCT03994172 VA Office of Research and Development Results posted	Completed	Phase 4	July 1, 2019
A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass NCT04003467 Entera Bio Ltd.	Completed	Phase 2	June 30, 2019
Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism NCT04126941 Hospices Civils de Lyon	Unknown status	—	June 1, 2019
Circulating Myokine Levels and Bone Metabolism NCT04206618 424 General Military Hospital	Completed	—	June 1, 2019
Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy NCT03702140 Shinshu University	Unknown status	Phase 2	October 9, 2018
G56W1 in Women With Postmenopausal Osteoporosis NCT03720886 Shenzhen Salubris Pharmaceuticals Co., Ltd.	Unknown status	Phase 1, Phase 2	October 1, 2018
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption NCT03710889 Radius Health, Inc. Results posted	Completed	Phase 3	September 20, 2018
Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism NCT03516773 Entera Bio Ltd.	Completed	Phase 2	June 17, 2018
Medication-related Osteonecrosis of the Jaw (MRONJ) Registry NCT02932501 AO Clinical Investigation and Publishing Documentation	Unknown status	—	August 14, 2017
Effect of Mechanical Loading With PTH on Cortical Bone NCT03232476 Massachusetts General Hospital	Withdrawn	Phase 4	Jul 2017

All 199 studies on ClinicalTrials.gov ↗

Source: ClinicalTrials.gov · verified October 30, 2026

Adverse event reports

Reports: 117,891
Serious: 47,322
With death outcome: 6,093

Most reported reactions

Nausea 9,220
Arthralgia 8,819
Dizziness 8,551
Pain in extremity 8,548
Fall 8,442
Pain 7,744
Fatigue 7,378
Back pain 6,091
Muscle spasms 5,818
Malaise 5,817
Headache 5,635
Asthenia 5,578

Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.

Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query

FDA prescribing information

Official US prescribing information. Dosing sections are intentionally not shown.

Forteo HUMAN PRESCRIPTION DRUG Eli Lilly and Company August 3, 2026
Teriparatide HUMAN PRESCRIPTION DRUG BluePoint Laboratories March 12, 2026
Teriparatide HUMAN PRESCRIPTION DRUG Amphastar Pharmaceuticals, Inc. December 22, 2025
Teriparatide HUMAN PRESCRIPTION DRUG Prasco Laboratories June 16, 2025

Source: DailyMed / openFDA

Change history

No changes since monitoring began on October 30, 2026.